⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250449 | 0.72 | — | — | |
| SCHEMBL11239632 | 0.65 | — | — | |
| SCHEMBL12435440 | 0.61 | — | — | |
| SCHEMBL10738207 | 0.61 | — | — | |
| SCHEMBL12818482 | 0.60 | — | — | |
| SCHEMBL20288915 | 0.58 | — | — | |
| SCHEMBL25338878 | 0.56 | — | — | |
| SCHEMBL12259908 | 0.56 | — | — | |
| SCHEMBL12569241 | 0.52 | CHRNB2 (0.31) | — | |
| SCHEMBL25163 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139479-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-07-27 | — | — | WO | disclosed |
| US-20220399510-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220145339-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-05-12 | — | — | US | disclosed |
| WO-2020120420-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-18 | — | — | WO | disclosed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-9567345-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008052804-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918286-A1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070178333-A1 | Organic electroluminescent device | FUJIFILM CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7211336-B2 | Organic electroluminescent device | FUJIFILM CORPORATION (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20070021433-A1 | Pharmacological chaperones for treating obesity | UNIVERSITE DE MONTREAL (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |